Use of pharmacokinetic and pharmacodynamic principles to determine optimal administration of daptomycin in patients receiving standardized thrice-weekly hemodialysis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 4, 2011, Pages 1677-1683

  Patel, Nimish ^a   Cardone, Katie ^a,b   Grabe, Darren W ^a,b   Meola, Shari ^c   Hoy, Christopher ^c   Manley, Harold ^d   Drusano, George L ^e   Lodise, Thomas P ^a,e  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Albany Nephrology Pharmacy ANephRx Group   (United States)

^c Hortense and Louis Rubin Dialysis Center   (United States)

^d Village Health Disease Management   (United States)

^e ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; CLINICAL ARTICLE; DIALYSATE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HEMODIALYSIS; HUMAN; MALE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

AGED; BACTEREMIA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; DAPTOMYCIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD; RENAL DIALYSIS; STAPHYLOCOCCUS AUREUS; TANDEM MASS SPECTROMETRY;

EID: 79953210748     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01224-10     Document Type: Article

References (18)

1. Allon, M. 2004. Dialysis catheter-related bacteremia: treatment and prophylaxis. Am. J. Kidney Dis. 44:779-791.
2. Bhavnani, S. M., C. M. Rubino, P. G. Ambrose, and G. L. Drusano. 2010. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin. Infect. Dis. 50:1568-1574.
3. Bowker, K. E., A. R. Noel, and A. P. MacGowan. 2009. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. J. Antimicrob. Chemother. 64: 1044-1051.
4. Cubist Pharmaceuticals, Inc. 2006. Cubicin (daptomycin) package insert. Cubist Pharmaceuticals, Inc., Brooks, KY.
5. Dandekar, P. K., P. R. Tessier, P. Williams, C. H. Nightingale, and D. P. Nicolau. 2003. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J. Antimicrob. Chemother. 52:405-411.
6. Eisenstein, B. I., F. B. Oleson, Jr., and R. H. Baltz. 2010. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin. Infect. Dis. 50(Suppl. 1):S10-S15.
7. Fowler, V. G., Jr., et al. 2006. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N. Engl. J. Med. 355:653-665.
8. Leary, R., R. Jelliffe, A. Schumitzky, and M. van Guilder. 2001. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p. 389-394. In Proceedings of the Fourteenth IEEE Symposium on Computer-Based Medical Systems. IEEE Computer Society, Bethesda, MD.
9. Louie, A., et al. 2001. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 45:845-851.
10. Oleson, F. B., Jr., et al. 2000. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob. Agents Chemother. 44:2948-2953.
11. Safdar, N., D. Andes, and W. A. Craig. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob. Agents Chemother. 48:63-68.
12. Salama, N. N., et al. 2009. Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin. J. Am. Soc. Nephrol. 4:1190-1194.
13. Salama, N. N., et al. 2010. Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Nephrol. Dial. Transplant. 25:1279-1284.
14. Sarnak, M. J., and B. L. Jaber. 2000. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int. 58:1758-1764.
15. Tokars, J. I., E. R. Miller, M. J. Alter, and M. J. Arduino. 1998. National surveillance of dialysis associated diseases in the United States, 1995. ASAIO J. 44:98-107.
16. Tokars, J. I., E. R. Miller, and G. Stein. 2002. New national surveillance system for hemodialysis-associated infections: initial results. Am. J. Infect. Control 30:288-295.
17. United States Renal Data System. 2008. USRDS 2008 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
18. United States Renal Data System. 2005. USRDS annual data report: atlas of end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.